Is end-stage methotrexate-related liver disease rare and associated with features of the metabolic syndrome?
The United States population burden of end-stage methotrexate-related liver disease is likely to be exceedingly small, suggesting the need for reappraisal of current hepatotoxicity surveillance guidelines. The risk factor profile of methotrexate-related liver disease supports the notion that it may share a common pathogenesis with NASH.
SLNB does not confer a survival benefit to children with melanoma, but it provides valuable prognostic information regarding MSS.